Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression

Microbes and Infection

Volumn 14, Issue 11, 2012, Pages 979-988

  Devos, Nathalie ^a   Tans, Christine ^a   Momin, Patricia ^a   Plisnier, Michel ^a   Weynants, Vincent ^a   Feron, Christiane ^a   Poolman, Jan T ^a,b  

^a GSK   (Belgium)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Factor H binding protein; Lipooligosaccharide; Neisseria meningitidis serogroup B; Polymerase chain reaction

Indexed keywords

BINDING PROTEIN; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; LIPOOLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; GENETIC ANALYSIS; GENOTYPE; GERMANY; NEISSERIA MENINGITIDIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPAIN; UNITED KINGDOM;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; GENOTYPING TECHNIQUES; HUMANS; LIPOPOLYSACCHARIDES; MASS SPECTROMETRY; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP B; POLYMERASE CHAIN REACTION; PREVALENCE; REPRODUCIBILITY OF RESULTS; SPAIN;

NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP B;

EID: 84865551147     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.04.005     Document Type: Article

References (40)

1. Khatami A., Pollard A.J. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev. Vaccines 2010, 9:285-298.
2. Scholten R.J.P.M., Kuipers B., Valkenburg H.A., Dankert J., Zollinger W.D., Poolman J.T. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 1994, 41:236-243.
3. Braun J.M., Beuth J., Blackwell C.C., Giersen S., Higgins P.G., Tzanakaki G., Unverhau H., Weir D.M. Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens. Vaccine 2004, 22:898-908.
4. Drabick J.J., Brandt B.L., Moran E.E., Saunders N.B., Shoemaker D.R., Zollinger W.D. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 1999, 18:160-172.
5. Zollinger W.D., Moran E.E., Devi S.J.N., Frasch C.E. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 1997, 65:1053-1060.
6. Estabrook M.M., Jarvis G.A., McLeod Griffiss J. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect. Immun. 2007, 75:1025-1033.
7. Weynants V., Denoël P., Devos N., Janssens D., Feron C., Goraj K., Momin P., Monnom D., Tans C., Vandercammen A., Wauters F., Poolman J.T. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun. 2009, 77:2084-2093.
8. Gidney M.A.J., Plested J.S., Lacelle S., Coull P.A., Wright J.C., Makepeace K., Brisson J.-R., Cox A.D., Moxon E.R., Richards J.C. Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis. Infect. Immun. 2004, 72:559-569.
9. Ram S., Cox A.D., Wright J.C., Vogel U., Getzlaff S., Boden R., Li J., Plested J.S., Meri S., Gulati S., Stein D.C., Richards J.C., Moxon E.R., Rice P.A. Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J. Biol. Chem. 2003, 278:50853-50862.
10. Moran E.E., Brandt B.L., Zollinger W.D. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 1994, 62:5290-5295.
11. Jones D.M., Borrow R., Fox A.J., Gray S., Cartwright K.A., Poolman J.T. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog. 1992, 13:219-224.
12. Tsai C.-M. Molecular mimicry of host structures by lipooligosaccharides of Neisseria meningitidis: characterization of sialylated and nonsialylated lacto-N-neotetraose (Galβ1-4GlcNAcβ1-3Galβ1-4Glc) structures in lipooligosaccharides using monoclonal antibodies and specific lectins. Adv. Exp. Med. Biol. 2001, 491:525-542.
13. Nairn C.A., Cole J.A., Patel P.V., Parsons N.J., Fox J.E., Smith H. Cytidine 5'-monophospho-N-acetylneuraminic acid or a related compound is the low Mr factor from human red blood cells which induces gonococcal resistance to killing by human serum. J. Gen. Microbiol. 1988, 134:3295-3306.
14. Estabrook M.M., McLeod Griffiss J., Jarvis G.A. Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect. Immun. 1997, 65:4436-4444.
15. Tsai C.-M., Mocca L.F., Frasch C.E. Immunotype epitopes of Neisseria meningitidis lipooligosaccharide types 1 through 8. Infect. Immun. 1987, 55:1652-1656.
16. Poolman J.T., Hopman C.T.P., Zanen H.C. Problems in the definition of meningococcal serotypes. FEMS Microbiol. Lett. 1982, 13:339-348.
17. Jolley K.A., Brehony C., Maiden M.C.J. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev. 2007, 31:89-96.
18. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., Ngampasutadol J., Vogel U., Granoff D.M., Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 2006, 177:501-510.
19. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.-H., Sim R.B., Tang C.M. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 2006, 176:7566-7575.
20. Jiang H.-Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., Scott A.A., Alexander K., Mason K., Miller L., DaSilva I., Mack M., Zhao X.-J., Pride M.W., Andrew L., Murphy E., Hagen M., French R., Arora A., Jones T.R., Jansen K.U., Zlotnick G.W., Anderson A.S. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
21. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Aricò B., Brunelli B., Pieri A., Santini L., Savino S., Serruto D., Litt D., Kroll S., Welsch J.A., Granoff D.M., Rappuoli R., Pizza M. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 2003, 197:789-799.
22. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., Ooi P., Smith R.P., Weise P., Wetherell M., Xie X., Zagursky R., Zhang Y., Zlotnick G.W. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 2004, 72:2088-2100.
23. Wright J.C., Hood D.W., Randle G.A., Makepeace K., Cox A.D., Li J., Chalmers R., Richards J.C., Moxon E.R. lpt6, a gene required for addition of phosphoethanolamine to inner-core lipopolysaccharide of Neisseria meningitidis and Haemophilus influenzae. J. Bacteriol. 2004, 186:6970-6982.
24. Kahler C.M., Lyons-Schindler S., Choudhury B., Glushka J., Carlson R.W., Stephens D.S. O-Acetylation of the terminal N-acetylglucosamine of the lipooligosaccharide inner core in Neisseria meningitidis. Influence on inner core structure and assembly. J. Biol. Chem. 2006, 281:19939-19948.
25. Choudhury B., Kahler C.M., Datta A., Stephens D.S., Carlson R.W. The structure of the L9 immunotype lipooligosaccharide from Neisseria meningitidis NMA Z2491. Carbohydr. Res. 2008, 343:2971-2979.
26. St.Michael F., Vinogradov E., Wenzel C.Q., McIntosh B., Li J., Hoe J.C., Richards J.C., Cox A.D. Phosphoethanolamine is located at the 6-position and not at the 7-position of the distal heptose residue in the lipopolysaccharide from Neisseria meningitidis. Glycobiology 2009, 19:1436-1445.
27. Beernink P.T., Leipus A., Granoff D.M. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin. Vaccine Immunol. 2006, 13:758-763.
28. Berrington A.W., Tan Y.-C., Srikhanta Y., Kuipers B., van der Ley P., Peak I.R.A., Jennings M.P. Phase variation in meningococcal lipooligosaccharide biosynthesis genes. FEMS Immunol. Med. Microbiol. 2002, 34:267-275.
29. Zhu P., Klutch M.J., Bash M.C., Tsang R.S.W., Ng L.-K., Tsai C.-M. Genetic diversity of three lgt loci for biosynthesis of lipooligosaccharide (LOS) in Neisseria species. Microbiology 2002, 148:1833-1844.
30. Alcalá B., Arreaza L., Salcedo C., Uría M.J., De La Fuente L., Vázquez J.A. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg. Infect. Dis. 2002, 8:1512-1514.
31. Castilla J., Vázquez J.A., Salcedo C., García Cenoz M., García Irure J.J., Torroba L., Beristain X., Abad R., Barricarte A. B:2a:p1.5 meningococcal strains likely arisen from capsular switching event still spreading in Spain. J. Clin. Microbiol. 2009, 47:463-465.
32. Uria M.J., Zhang Q., Li Y., Chan A., Exley R.M., Gollan B., Chan H., Feavers I., Yarwood A., Abad R., Borrow R., Fleck R.A., Mulloy B., Vazquez J.A., Tang C.M. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J. Exp. Med. 2008, 205:1423-1434.
33. Jarva H., Ram S., Vogel U., Blom A.M., Meri S. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 2005, 174:6299-6307.
34. Lewis L.A., Ngampasutadol J., Wallace R., Reid J.E.A., Vogel U., Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010, 6:e1001027.
35. Cunha C.Sa E., Griffiths N.J., Virji M. Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells. PLoS Pathog. 2010, 6:e1000911.
36. Griffiths N.J., Hill D.J., Borodina E., Sessions R.B., Devos N.I., Feron C.M., Poolman J.T., Virji M. Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance. Mol. Microbiol. 2011, 82:1129-1149.
37. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27:2794-2803.
38. Jacobsson S., Thulin S., Mölling P., Unemo M., Comanducci M., Rappuoli R., Olcén P. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006, 24:2161-2168.
39. Pajón R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129.
40. Lucidarme J., Tan L., Exley R.M., Findlow J., Borrow R., Tang C.M. Characterisation of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen, factor H binding protein. Clin. Vaccine Immunol. 2011, 18:1002-1014.